The entire stake was acquired by Kotak Mahindra Mutual Fund at the same price. The deal comes less than two years after Emcure Pharmaceuticals’ public listing and is among the larger block transactions in the pharmaceutical sector this year.
Shares changed hands at Rs 1,700 apiece, a discount to the prevailing market price, a common feature in large institutional transactions aimed at facilitating bulk stake sales.
Emcure has been in focus among analysts due to its strong positioning in chronic therapies and improving export prospects.
According to a recent note by YES Securities, the company is expected to benefit from multiple growth drivers over the next few years. Its core gynaecology franchise, one of the strongest in the domestic pharmaceutical market, is projected to deliver double-digit growth aided by its iron deficiency portfolio and a moderation in the drag from ferric carboxymaltose products in the hospital business.
The brokerage also highlighted opportunities from new product launches in emerging categories within women’s healthcare and the company’s distribution arrangement for legacy cardiac and diabetes brands acquired from Sanofi. Analysts believe the partnership could help Emcure strengthen specialist doctor engagement and support growth in its own cardiology portfolio.
On the international front, Emcure is expected to benefit from the scale-up of Amphotericin B production from dedicated manufacturing facilities, supporting growth in export revenues.YES Securities estimates that Emcure could deliver revenue growth of 12-13% annually over the next three years, accompanied by a gradual improvement in operating margins.
The company has built a diversified pharmaceutical business spanning women’s health, cardiology, blood-related therapies, oncology and international formulations. It also maintains a growing presence in regulated and emerging export markets.
